MEDICUS PHARMA LTD. Increase (Decrease) in Accounts Payable, Related Parties
MEDICUS PHARMA LTD. (MDCX) reported Increase (Decrease) in Accounts Payable, Related Parties of $45.37 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties · last filed 2026-08-12
- MEDICUS PHARMA LTD. increase (decrease) in accounts payable, related parties for the quarter ending 2026-06-30 was $14.62K, a 378.19% increase year-over-year.
- MEDICUS PHARMA LTD. increase (decrease) in accounts payable, related parties for the quarter ending 2026-03-31 was $30.75K.
- MEDICUS PHARMA LTD. increase (decrease) in accounts payable, related parties for the quarter ending 2025-12-31 was -$26.60K.
- MEDICUS PHARMA LTD. increase (decrease) in accounts payable, related parties for the quarter ending 2025-09-30 was $21.81K, a 162.04% increase year-over-year.
- MEDICUS PHARMA LTD. increase (decrease) in accounts payable, related parties for fiscal 2025 was -$25.98K.
- MEDICUS PHARMA LTD. increase (decrease) in accounts payable, related parties for fiscal 2024 was -$23.49K, a 114.16% decline from fiscal 2023.
- MEDICUS PHARMA LTD. increase (decrease) in accounts payable, related parties for fiscal 2023 was $165.95K.
| Period end | Increase (Decrease) in Accounts Payable, Related Parties 3 month | Increase (Decrease) in Accounts Payable, Related Parties 6 month | Increase (Decrease) in Accounts Payable, Related Parties 9 month | Increase (Decrease) in Accounts Payable, Related Parties 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.62K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $45.37K 10-Q · filed 2026-08-12 | $18.77K derived: sum of 3 quarters · filed 2026-08-12 | $40.57K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $30.75K 10-Q · filed 2026-05-14 | $4.14K derived: sum of 2 quarters · filed 2026-05-14 | $25.95K derived: sum of 3 quarters · filed 2026-05-14 | $29.01K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$26.60K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$4.80K derived: sum of 2 quarters · filed 2026-03-25 | -$1.74K derived: sum of 3 quarters · filed 2026-08-12 | -$25.98K 10-K · filed 2026-03-25 |
| 2025-09-30 | $21.81K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $24.86K derived: sum of 2 quarters · filed 2026-08-12 | $621.00 10-Q · filed 2025-11-14 | -$342.00 derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $3.06K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$21.19K 10-Q · filed 2026-08-12 | -$22.15K derived: sum of 3 quarters · filed 2026-08-12 | -$13.83K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$24.24K 10-Q · filed 2026-05-14 | -$25.21K derived: sum of 2 quarters · filed 2026-05-14 | -$16.89K derived: sum of 3 quarters · filed 2026-05-14 | -$95.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$963.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $7.36K derived: sum of 2 quarters · filed 2026-03-25 | -$70.76K derived: sum of 3 quarters · filed 2026-03-25 | -$23.49K 10-K · filed 2026-03-25 |
| 2024-09-30 | $8.32K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$69.79K derived: sum of 2 quarters · filed 2025-11-14 | -$22.53K 10-Q · filed 2025-11-14 | |
| 2024-06-30 | -$78.12K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$30.85K 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $47.27K 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $165.95K 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B |